Results 261 to 270 of about 131,254 (306)
Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models. [PDF]
J Immunother CancerMinnee J +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Chimeric Antigen Receptor Design Today and Tomorrow
The Cancer Journal, 2021Abstract The US Food and Drug Administration has approved 3 chimeric antigen receptor (CAR) T-cell therapies. For continued breakthroughs, novel CAR designs are needed. This includes different antigen-binding domains such as antigen-ligand binding partners and variable lymphocyte receptors.
Justin C, Boucher, Marco L, Davila
openaire +2 more sources
Chimeric Antigen Receptors for the Tumour Microenvironment
2020Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option.
Rosemary, Habib +3 more
openaire +2 more sources
4-1BB Chimeric Antigen Receptors
The Cancer Journal, 2014In addition to T-cell receptor signals, T lymphocytes require costimulatory signals for robust activation. Among these, those mediated by 4-1BB (CD137, TNFRSF9) are critical for tumor immunity. 4-1BB is expressed in T-cell receptor-activated lymphocytes as well as natural killer cells and other hematopoietic and nonhematopoietic cells.
Dario, Campana +2 more
openaire +2 more sources
Structural Determinants of Chimeric Antigen Receptor Design
Critical Reviews in Immunology, 2021Chimeric antigen receptor (CAR) T cell therapy consists of the gene transfer of a cassette encoding a receptor capable of redirecting the transduced T cell toward a specific cytotoxic response against tumor cells. The therapy has been providing a new perspective on some hematologic malignancies, such as CD19+ lymphomas and acute lympho-blastic leukemia.
Luiza, Abdo +2 more
openaire +2 more sources
Chimeric Antigen Receptors for Cancer Immunotherapy
2016The adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) has emerged as a promising treatment for various lymphoid and solid malignancies. Patients treated with CAR-T cells have achieved dramatic responses and in some cases, complete tumor eradication.
Claudia, Geldres +2 more
openaire +2 more sources
Imaging Chimeric Antigen Receptor (CAR) Activation
2020The chimeric antigen receptor (CAR) has been extensively exploited in cancer immunotherapy. In spite of the success of CAR T cells in clinical applications, the molecular mechanism underlying CAR-T cell activation remains unclear. Key questions remain: how are CARs activated by tumor antigens?
Kendra A, Libby, Xiaolei, Su
openaire +2 more sources
Chimeric antigen receptor T-cell toxicity
Current Opinion in Pediatrics, 2019Purpose of review Chimeric antigen receptor -(CAR) T-cell therapy has become a commonly used immunotherapy originally used in the treatment of B-cell leukemias but which are now applied broadly across tumor classes. Although high rates of remission are associated with CAR T-cell therapy, toxicities associated with these novel ...
DaMarcus E, Baymon, Edward W, Boyer
openaire +2 more sources
Advances in chimeric antigen receptor T cells
Current Opinion in Hematology, 2020Purpose of review To discuss the important advances in CAR T cell therapy over the past year, focusing on clinical results where available. Recent findings Approximately 30 years after they were first conceived of and 15 years after the first small-scale single-center clinical ...
Ofrat, Beyar-Katz, Saar, Gill
openaire +2 more sources